A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma

Annals of Oncology

Volumn 13, Issue 9, 2002, Pages 1469-1478

  McDonald, A C ^a   Evans, T R J ^a   Pentheroudakis, G ^a   Paul, J ^a   McInnes, A ^a   Blackie, R ^a   Raby, N ^b   Morrison, R ^a   Fullarton, G M ^c   Soukop, M ^d  

^a CRC Department of Medical Oncology   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Capecitabine; Cisplatin; Epirubicin; Oesophago gastric cancer

Indexed keywords

CAPECITABINE; CISPLATIN; DOXIFLURIDINE; EPIRUBICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; ESOPHAGITIS; ESOPHAGUS CARCINOMA; ESOPHAGUS SURGERY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH SURGERY; STOMATITIS; THROMBOCYTOPENIA;

EID: 0036740439     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf243     Document Type: Article

References (31)

1. Allum WH, Powell DJ, McConkey CC, Fielding JW. Gastric cancer - a 25 year review. Br J Surg 1989; 76: 535-540.
2. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
3. Glimelius B, Hoffman K, Haglund U et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5: 189-190.
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
5. Findlay M, Cunningham D, Normal A et al. A phase II study in advanced gastro-oesophageal cancer using epuribicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609-616.
6. Highley MS, Parnis FX, Trotter GA et al. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma. Br J Surgery 1994; 81: 1763-1765.
7. Zaniboni A, Barni S, Labianca R et al. Epirubicin, cisplatin and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer report. Cancer 1995; 76: 1694-1699.
8. Webb A, Cunningham D, Scarffe JH et al. Randomised trial comparing epuribicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced oesophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
9. Evans TRJ, Lofts FJ, Mansi JL et al. A phase II study of continuous infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 1996; 73: 1260-1264.
10. Kikuyama S, Inada T, Shimizu K, Miyakita M. Thymidine phosphorylase expression in gastric cancer in association with proliferative activity and angiogenesis. Anticancer Res 2000; 20: 2081-2086.
11. Ogawa K, Konno S, Takebayashi Y et al. Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma. Anticancer Res 1999; 19: 4363-4367.
12. Ikeguchi M, Oka, S, Saito H et al. The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma. Anticancer Res 1999; 19: 4001-4005.
13. Saito H, Tsujitani S, Oka S et al. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer 1999; 81: 484-489.
14. Takahashi Y, Bucana CD, Akagi Y et al. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 1998; 4: 429-434.
15. Maeda K, Kang SM, Ogawa M et al. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial growth factor expression in gastric carcinoma. Int J Cancer 1997; 74: 545-550.
16. Tanigawa N, Amaya H, Matsumura M et al. Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Lett 1996; 108: 281-290.
17. Maeda K, Chung YS, Ogawa Y et al. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 1996; 73: 884-888.
18. Takebayashi Y, Miyadera K, Akiyama S et al. Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 1996; 87: 288-295.
19. Koizumi W, Saigenji K, Nakamura N et al. Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology 1999; 56: 215-222.
20. Suda Y, Kuwashima Y, Shioya T et al. The expression of thymidylate synthase and thymidine phosphorylase in the early-stage of gastric cancer. Jpn J Cancer Chemother 1999; 26: 321-327.
21. Shimaoka S, Matsushita S, Nitanda T et al. The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma. Cancer 2000; 88: 2220-2227.
22. Mackean M, Planting A, Twelves C et al. Phase I and pharmacodynamic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16: 2977-2985.
23. Schuller J, Cassidy K, Dumont E et al. Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297.
24. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomised phase II study. J Clin Oncol 2000; 18: 1337-1345.
25. Blum JL, Jones SE, Buzdar AU et al. Multi-center phase II study of capecitabine in paclitaxel - refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493.
26. Green S, Weiss GR. South West Oncology Group Standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
27. Reigner B, Verweij J, Dirix L et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998; 4: 941-948.
28. Takahashi Y, Mai M, Taguchi T et al. Prolonged stable disease affects survival in patients with solid gastric tumour: analysis of phase II studies of doxifluridine. Int J Oncol 2000; 17: 285-289.
29. Takiguchi N, Nakajima N, Saitoh N et al. A phase III randomised study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer. Int J Oncol 2000; 16: 1021-1027.
30. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomised phase III study. J Clin Oncol 2001; 19: 2282-2292.
31. Seymour MT, Dent JT, Papamichael D et al. Epirubicin, cisplatin, and oral UFT with leucovorin (ECU): a phase I-II study in patients with advanced upper gastrointestinal tract cancer. Ann Oncol 1999; 10: 1329-1333.